
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- hexemb.io
- Total Funding
- $17.9M
- Last Round
- $10.4M SeedApr 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 8 investors for this company. The full record is or through the API.
About
heXembio is a longevity therapeutics company developing the world's first rejuvenated hematopoietic stem cell therapy. Its platform restores the regenerative power of aged blood stem cells using a synthetic biology approach validated in peer-reviewed research published in Nature. The technology targets aging, immune health, and hematological conditions.
Summary
It lists 1–10 employees. It has raised $17.9M in total across 2 rounds, most recently a $10.4M Seed round in Apr 2026. Investors include Draper Associates, SOSV and Zentynel.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Apr 2026
Sign up to see all 2 events
Funding: Seed. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/hexembio"><img src="https://indexed.vc/api/badge/company/hexembio" alt="heXembio on Indexed.vc" width="260" height="76" /></a>

